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The primary chemical mediators of immediate 
type hypersensitivity include histamine. the eosin-
ophil chemotactic facto r of anaphylaxis (E CF -A), 
slow reacting su bstance of anaphylaxis (SRS-Al. 
and platelet activating factor (P AF ). These media-
tors exist either preformed or are newly generated 
and subsequently released following activation of 
the target cell. The nature of these mediators, their 
interrelationships. the b iochemical concomitants. 
and controls over their generat ion and release are 
the focus of this review. 
All four primary mediators have been associated 
with the human peripheral blood basophil [1] and 
the human tissue mast cell [2-4]. Histamine and 
E CF-A exist preformed and are granule assoc iated 
[4] while SRS-A and PAF must be generated prior 
to their release. These mediators may be generated 
and released following the interact ion of an tigen 
and specific IgE antibody bound to receptors on 
the surface of t he mast cell or basophils, or 
following interaction of mast cells or basophils wii h 
antibody directed toward the IgE molecule itself. 
Upon the bridging of two or more IgE molecules 
upon t he surface of the target cell. a series of 
biochemically separable steps ensues, resulting in 
the generation of unsto red mediato rs and culml-
nat ing in the release of both the generated and 
prefo rmed mediators. 
Temporally. the fi rst step in the sequence thus 
far delineated is the activation of a proesterase to 
an active di isopropyU1uorophosphate (DFP1-inhib-
itable serine esterase. This enzyme, in the pre ence 
of calcium ions appears to have autocataly tic 
properties [5] . Following the DFP-sensitive step is 
an energy-dependent. 2-deoxyglucose-inhibitable 
step and fin ally a divalent cation. EDTA-inhibita-
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EDTA: ethylenediamine tetraacetic acid 
PAF: platelet activating fact.o r 
SRS-A: slow reacting su bstance of anaphylaxis 
ble reaction [5 ]. The nu cleotides cyclic adenosine 
monophospha te (cAMP) and cyclic guanosine 
phosphate (cGMP ) in concert with t.hese biochem i-
cal processes manifest another level of control and 
act to modulate t he release of media tors from 
target t issues. Beta adrenergi c s t imulation . 
int.eraction with cholera tox in. prost.agland ins of 
the E series or methyl xanthines lead to the 
accumulation of cAMP and decreased mediator 
release [6 j, while al pha adrenergic stimuli. or 
interaction with small amounts of prostaglandins 
of the F series , lead to decreases in cAM P a nd 
augmentation of mediator release [7]. Moreover. 
the exogenous addit ion of analogues of cG M P or 
cholenergic stimu li which presumably act to ele-
vate int racellular concentrations of cGMP also 
augment mediator release [6 ]. The exact step or 
steps in the reaction seq uence of generation and 
release of mediators modulated by the cyclic 
nucleotides is unclear and may include both con-
trol over the generation of mediators as well as 
release. perhaps via alterations in the alignment of 
microtubles and microfi laments. 
An understanding of the chemical and fum·tiona l 
nature of the specific facto rs released pro\'ides the 
basis fo r an approach to unravelling the mecha-
nisms underlying pathobiologic alterations mani-
rest by disease states . The preformed mediator 
histamine is formed from L-histid ine and inacti-
vated by oxidative deaminati on with or withom 
methylation [8]. In vivo h istamine is known to 
alter venula r permeabi lity and to stimulate the 
resp iratory irri tant receptor [9] and to constrict 
bronchial smooth muscle. 
ECF-A is also preformed [4 J and is an 
acid ic, approximately 400 mw te trapeptide [lOJ of 
limited heterogeneity . E CF -A preferent.ially 
a ttrac ts and chem otactically deactivate eosino-
phils [111. It is suscept ible to pronase and subtilin 
digestion but resists trypsin or chymotrypsi n deg-
radation [12]. E CF-A preferentially attracts eo-
sinophils and is the most potent eosinophil otactic 
factor when com pared to active site or complement 
der ived che motactic facto rs [13]. Followin g 
interaction with ECF-A, eosinophils reveal dimin-
ished responsiveness to subsequent chemotactic 
stimulation, termed deactiva t ion, a phenomenon 
presumed to allow attracted eosinophi ls to remain 
at a site and exert a regulatory function . 
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SRS-A is an acidic sulfur containing 300 mw lipid 
[14] inactivated by limpet [15] or human eosino-
phil [11] arylsulfatase. SRS-A can be found imme-
diately prior to release in tissues following activa-
tion [16). SRS-A has been presumed to originate in 
mast cells or basophils ba ed upon its generation 
by IgE dependent reaction in human mast cell-rich 
tissues [3. I i I. peri pheral blood leukocytes [l8], or 
ionophore activation of leukemic basophils [I). 
SRS-A can be appreciated intracellularly following 
levels of activation below threshold for histamine 
release [16). and following greater degrees of chal-
lenge, release proceeds beyond the time of plateau 
for histamine or ECF-A release [16]. Furthermore, 
the release of SRS-A can be augmented markedly 
by the addition of c:ysteine to the reaction medium 
[19). SR -A may also be generated in rodent tis-
'ues by a n 19Ga. neutrophil. and complement-
dependent mechanism [20]. SR -A in vivo con-
tracts smooth muscle. enhances vascular permea-
bility [21], and decreases pulmonary compl ia nce 
[221. 
PAF. defined by its ability to mediate serotonin 
release from platelets. has been appreciated follow-
ing IgE-dependent reactions in human lung [23) 
and peri pheral blood leukocyte suspension [24 1 
and by calcium ionophore activation of human 
leukemic basophils. PAF generated by an IgG a-
dependent reaction in the rat peritoneal cavity has 
an m w of :300 and is stable to arylsulfatase but 
sensi t ive to eosinophil phospholipase D enzymatic 
degradation [25). The exact-functional properties 
of this factor in \'ivo a re unknown. 
The possible fu nctional interrelationships of 
these chemical mediators are mainly specula tive. 
It is known that histamine and SRS-A potentiate 
one another in bronchial smooth muscle trips [26) 
and may ac t synergistically in vascular smooth 
muscle as well. It is also possible that these 
primary mediators may induce the product ion of 
such secondary mediators as prostaglandins or 
kinins . Finally. it should be noted that the poten-
tial for de. truction of three of these primary 
mediators is inherent in the propert ies of the 
fourth. That is. ECF-A. b~' attracting eosinophil. 
attracts and localizes to the site of mediator release 
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a cell which contains histaminase to inactivate 
histamine [27], arylsulfatase B to inactivate 
SRS-A [15], and pho pholipa e D to inactivate 
PAF [28). 
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